Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
• Brain Injury Program:
– Exploratory study shows new lead drug candidate NYR-BI02 could be taken orally, offers potential new treatment for concussion
– Minimal impact from COVID-related lockdowns in China
– Results from preclinical stroke model study expected mid Q2 CY2022
– Phase I study to commence in 2H CY2022, evaluating safety and tolerability of NYR-BI02 to support clinical development in TBI and stroke
• Cholesterol-Lowering Program:
– COVID-related lockdowns in China impact drug manufacture by Shanghai-based CRO delaying start of preclinical studies to Q3 CY2022
– Phase I first-in-human study to commence late 2H CY2022
• Robust cash position of A$11.3 million: includes R&D tax incentive rebate of A$1.3 million received in January 2022